| Valeria Possick, MD | |
|
84 N Main St Bldg 2, Branford, CT 06405-3061 | |
| (203) 483-2024 | |
| (203) 483-2520 |
| Full Name | Valeria Possick |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 16 Years |
| Location | 84 N Main St Bldg 2, Branford, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902210818 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 60440 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Griffin Hospital | Derby, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrated Anesthesia Associates Llc | 1759281165 | 373 |
News Archive
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
Despite aggressive treatment, glioblastoma multiforme (GBM) - the most common and deadly of brain cancers - usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain.
A drug called etanercept can restore responsiveness to the pain-relieving effects of morphine in rats that have developed morphine tolerance, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of HDL (the "good" cholesterol) to treat cardiovascular and other metabolic diseases, announced today it has raised €40 million in the first close of its series C financing. In this round €20 million came from the Fund for Strategic Investment (FSI) with an additional €20 million coming from the existing investors: Sofinnova Partners, HealthCap, Alta Partners and TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.
› Verified 6 days ago
| Entity Name | Integrated Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881636397 PECOS PAC ID: 1759281165 Enrollment ID: O20040112000163 |
News Archive
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
Despite aggressive treatment, glioblastoma multiforme (GBM) - the most common and deadly of brain cancers - usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain.
A drug called etanercept can restore responsiveness to the pain-relieving effects of morphine in rats that have developed morphine tolerance, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of HDL (the "good" cholesterol) to treat cardiovascular and other metabolic diseases, announced today it has raised €40 million in the first close of its series C financing. In this round €20 million came from the Fund for Strategic Investment (FSI) with an additional €20 million coming from the existing investors: Sofinnova Partners, HealthCap, Alta Partners and TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Valeria Possick, MD 2408 Whitney Ave, Hamden, CT 06518-3209 Ph: (203) 483-2024 | Valeria Possick, MD 84 N Main St Bldg 2, Branford, CT 06405-3061 Ph: (203) 483-2024 |
News Archive
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
Despite aggressive treatment, glioblastoma multiforme (GBM) - the most common and deadly of brain cancers - usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain.
A drug called etanercept can restore responsiveness to the pain-relieving effects of morphine in rats that have developed morphine tolerance, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of HDL (the "good" cholesterol) to treat cardiovascular and other metabolic diseases, announced today it has raised €40 million in the first close of its series C financing. In this round €20 million came from the Fund for Strategic Investment (FSI) with an additional €20 million coming from the existing investors: Sofinnova Partners, HealthCap, Alta Partners and TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.
› Verified 6 days ago
Francisco O Rivera Ferrer, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 84 N Main St, Branford, CT 06405 Phone: 203-483-2024 Fax: 203-483-2520 | |
Marion S Grabowy, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 84 N Main St, Branford, CT 06405 Phone: 203-483-2024 Fax: 203-483-2520 |